The American Cancer Society and Flatiron Health Announce Recipients of Real-World Data Impact Award
Retrieved on:
Monday, October 25, 2021
NEW, Breast cancer, American Cancer Society, Research, ACS, University, Disease, Cancer Epidemiology, Biomarkers & Prevention, Goal, RWD, Neoplasm, Hoffmann-La Roche, Epidemiology, Patient, Journal of Clinical Oncology, Policy, Cancer prevention, MS, Data, Hormone receptor positive breast tumor, H. Lee Moffitt Cancer Center & Research Institute, Fox Chase Cancer Center, Flatiron Institute, EHR, MPH, Health, Data science, Control, Columbia University, Toxicity, Academic health science centre, Doctor of Philosophy, Chief scientific officer, AACR, Biomarker, ASCO, Pharmaceutical industry, Medical imaging
ATLANTA and NEW YORK, Oct. 25, 2021 /PRNewswire/ -- The American Cancer Society (ACS) and Flatiron Health announced today that the 2021 Real-World Data Impact Awards will support research into health disparities among patients with advanced pancreatic and breast cancer.
Key Points:
- ATLANTA and NEW YORK, Oct. 25, 2021 /PRNewswire/ -- The American Cancer Society (ACS) and Flatiron Health announced today that the 2021 Real-World Data Impact Awards will support research into health disparities among patients with advanced pancreatic and breast cancer.
- "Flatiron Health is honored to partner with ACS to leverage Flatiron's EHR-derived real-world data to advance research toward better and more equitable cancer treatments and outcomes," said Rebecca Miksad, MD, MPH, senior medical director at Flatiron Health.
- Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow.
- Flatiron.com @FlatironHealth
The American Cancer Society is on a mission to free the world from cancer.